(:CHX*CA)
Business Focus: N/A
Jul 04, 2018 04:54 pm ET
ChroMedX Announces Results of Annual General Meeting and Name Change
Toronto, Ontario--(Newsfile Corp. - July 4, 2018) - ChroMedX Corp., (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the results of the annual general meeting held on June 29, 2018. All matters presented to the shareholders were approved including the change of the Company's name to Relay Medical Corp.
Jun 20, 2018 04:10 pm ET
ChroMedX Appoints Tom Glawdel as Chief Scientific Officer and HemoPalm Science Lead
Toronto, Ontario--(Newsfile Corp. - June 20, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Tom Glawdel, PhD as Chief Scientific Officer and HemoPalm science lead effective immediately.
Jun 19, 2018 04:10 pm ET
ChroMedX Announces Expansion and Launch as Relay Medical Corp.
Toronto, Ontario--(Newsfile Corp. - June 19, 2018) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to report on the Company's expansion into a Medtech incubator/accelerator platform and launch as Relay Medical Corp. The formal name change will take place following the Company's Annual General Meeting on June 29, 2018.
May 24, 2018 07:36 pm ET
ChroMedX Acquires UX Data Sciences Corp.
Toronto, Ontario--(Newsfile Corp. - May 24, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the closing of its previously announced acquisition (the "Transaction") of the Ottawa, Ontario based medtech data science company, UX Data Sciences Corp. ("UXD").
May 09, 2018 12:02 pm ET
IIROC Trade Resumption - CHX
VANCOUVER, May 9, 2018 /CNW/ - Trading resumes in:
May 09, 2018 11:41 am ET
ChroMedX Signs Deal to Acquire UX Data Sciences Corp.
Toronto, Ontario--(Newsfile Corp. - May 9, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce that it has entered into a binding Letter-of-Intent ("LOI") to acquire Ottawa, Ontario based medtech data science company, UX Data Sciences Corp. ("UXD").
May 09, 2018 09:09 am ET
IIROC Trading Halt - CHX
VANCOUVER, May 9, 2018 /CNW/ - The following issues have been halted by IIROC:
May 08, 2018 09:13 am ET
ChroMedX Reports on HemoPalm Techno-Commercial Analysis and Productization Plan
Toronto, Ontario--(Newsfile Corp. - May 8, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company") developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to report on HemoPalm activities.
Apr 13, 2018 04:05 pm ET
ChroMedX Appoints Michaela Shaw as Director of Quality Assurance and Regulatory Assurance
Toronto, Ontario--(Newsfile Corp. - April 13, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Michaela Shaw as Director of Quality Assurance and Regulatory Assurance.
Mar 27, 2018 04:35 pm ET
ChroMedX CEO Lahav Gil Invited to Speak on Industry Panel at bioTEC, Biotechnology and Bioengineering Conference
Toronto, Ontario--(Newsfile Corp. - March 27, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company") , developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce that CEO Lahav Gil will speak at the 2018 bioTEC Conference at the University of Waterloo to discuss innovation culture and Medtech commercialization.
Mar 21, 2018 06:27 pm ET
ChroMedX Accelerates Software Development and Implementation Activities; Appoints iGAL Roytblat, Formerly of Kangaroo Group, as CTO, Amid Expansion
Toronto, Ontario--(Newsfile Corp. - March 21, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce an update on the acceleration of software development and implementation activities led by newly appointed Chief Technology Officer (CTO) iGAL Roytblat.
Mar 19, 2018 04:05 pm ET
ChroMedX Appoints Raj Kailasanathan as Executive Vice President Corporate Finance
Toronto, Ontario--(Newsfile Corp. - March 19, 2018) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce the appointment of Raj Kailasanathan as ChroMedX Corp. Executive Vice President, Corporate Finance.
Feb 15, 2018 04:05 pm ET
ChroMedX CEO Lahav Gil Assembles Task-Force to Explore Feasibility and Applications of Automated Ultrafiltration Technology
Toronto, Ontario--(Newsfile Corp. - February 15, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the formation of an evaluation team for the analysis of the Company's patented Automated Ultrafiltration Technology (AUF).
Jan 23, 2018 04:05 pm ET
ChroMedX Appoints Dr. Richard Janeczko as Chief Commercial Officer; Jessica Kuhn as Chief Operations Officer
Toronto, Ontario--(Newsfile Corp. - January 23, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointments of Dr. Richard Janeczko as Chief Commercial Officer (CCO) and Jessica Kuhn as Chief Operations Officer (COO). Dr. Janeczko and Ms. Kuhn's positions are effective immediately.
Jan 05, 2018 04:07 pm ET
ChroMedX Corp. Expands Executive Team; Lahav Gil Appointed CEO and Director
Toronto, Ontario--(Newsfile Corp. - January 5, 2018) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointments of MedTech visionary Lahav Gil as Chief Executive Officer and W. Clark Kent as President of the Company. Both have also been appointed to the Company's board of directors.
Jan 03, 2018 04:05 pm ET
ChroMedX Corp. Executes Definitive Agreement with DxEconomix to Lead Value-Based Transactions
Toronto, Ontario--(Newsfile Corp. - January 3, 2018) - ChroMedX Corp. (CSE: CHX) (OTC: CHXIF) (FSE: EIY2), (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to report on the signing of a definitive agreement with diagnostic marketing experts DxEconomix Inc. (DxEx) to conduct a high value transaction for the Company.
Dec 13, 2017 04:05 pm ET
ChroMedX Announces Exercise of Warrants
Toronto, Ontario--(Newsfile Corp. - December 13, 2017) - ChroMedX Corp. (CSE: CHX) (OTC: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that since November 2017 investors have exercised warrants to acquire 1,031,000 new common shares of the Company as of December 12, 2017.
Dec 07, 2017 06:55 pm ET
ChroMedX Strengthens Board of Directors with the Appointment of Dr. Richard Janeczko
Toronto, Ontario--(Newsfile Corp. - December 7, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the appointment of Dr. Richard Janeczko to the Company's Board of Directors. This appointment is consistent with the Company's strategy to strengthen its business development and commercialization team through the addition of an experienced executive who brings hands-on business, diagnostics, operational and technical expertise.
Dec 01, 2017 04:15 pm ET
ChroMedX Announces In-House Biosensor Manufacturing for Expedited Testing and Refinement; Appoints Edwards as Executive Chairman
Toronto, Ontario--(Newsfile Corp. - December 1, 2017) - ChroMedX Corp. (the "Company") (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to report that the Company is now in the process of mass manufacturing the HemoPalm's biosensor component at the ChroMedX lab in Ontario, Canada. The Company also announces the appointment of Gerard Edwards as Executive Chairman, and George Langdon as Corporate Communications Director.
Nov 24, 2017 05:19 pm ET
ChroMedX Accepts Proposal; Signs LOI with Diagnostic Marketing Experts to Conduct a Value-Based Transaction for the HemoPalm Blood Analyzer System
Toronto, Ontario--(Newsfile Corp. - November 24, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company"), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce that it has entered into a binding Letter of Intent ("LOI") with Glendale, California headquartered diagnostic marketing specialist Dx Econmix Inc. (DxEx) to conduct a high value transaction for the Company. The Company is now working with DxEconomix to establish a definitive agreement with a view to maximize shareholder value.
Nov 20, 2017 05:20 pm ET
ChroMedX Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - November 20, 2017) - ChroMedX Corp. (CSE: CHX) (OTCQB: CHXIF) (FSE: EIY2) (the "Company") is pleased to announce that it has closed a non-brokered private placement (the "Offering") of 7,570,500 units ("Units") at a price of $0.20 per Unit for aggregate gross proceeds of $1,514,100. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to acquire one Common Share at a price of $0.30 for a period of two years from the closing of the Offering.
Nov 13, 2017 04:04 pm ET
ChroMedX appoints Ants Kahu & Associates to Implement Quality Management System
Toronto, Ontario--(Newsfile Corp. - November 13, 2017) - ChroMedX Corp. (the "Company") (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the engagement of Ants Kahu & Associates to implement Quality Management Systems to meet FDA and ISO requirements.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.